Accustem Sciences Inc.
Accustem Sciences Inc. (ACUT): 29 pipeline candidates · 3 upcoming catalysts · 24 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E -1.40 · 0% dilution
Lead: Phase 3
29 candidates
3 upcoming, next in ~1262d
N/A
A transparent, data-derived signal for Accustem Sciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.7M
Cash
—
Quarterly Burn
$374K
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (29 candidates)
| Drug | Phase |
|---|---|
| 1.5 x 10^6 UC-MSC + CM | Phase 2 |
| 2D UC-MSC group | Phase 1 |
| 3D hypoxia-preconditioned UC-MSC group | Phase 1 |
| 5 x 10^6 UC-MSC + CM | Phase 2 |
| ADSTEM Inj. | Phase 3 |
| alemtuzumab | Phase 1 |
| Allogeneic HB-adMSCs | Phase 1 |
| Allogeneic Umbilical Cord Mesenchymal Stem Cell | Phase 1 |
| Avelumab | Phase 1 |
| belatacept | Phase 1 |
Showing 10 of 29 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in Accustem Sciences Inc.'s pipeline?
Accustem Sciences Inc. (ACUT) has 29 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Accustem Sciences Inc.'s lead drug candidate?
Accustem Sciences Inc.'s most advanced tracked candidate is 1.5 x 10^6 UC-MSC + CM (Phase 2) for Retinitis Pigmentosa.
What is Accustem Sciences Inc.'s next catalyst?
Accustem Sciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the" — expected December 1, 2029.
What is Accustem Sciences Inc.'s market capitalization?
Accustem Sciences Inc.'s market capitalization is approximately $3.7M.
Who is the CEO of Accustem Sciences Inc.?
Ms. Wendy E. Blosser is the chief executive officer of Accustem Sciences Inc. (ACUT).
Get the full picture on Accustem Sciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.